{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:29Z","timestamp":1791404549392,"version":"4.3.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1002\/jps.20289","type":"journal-article","created":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T19:40:05Z","timestamp":1109187605000},"page":"788-797","source":"Crossref","is-referenced-by-count":33,"title":["Mass Spectral Analyses of Labile DOTA-NHS and Heterogeneity Determination of DOTA or DM1 Conjugated Anti-PSMA Antibody for Prostate Cancer Therapy"],"prefix":"10.1016","volume":"94","author":[{"given":"Sharon X.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Takach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Say-Jong","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Y.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.20289_bb0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/mthe.2002.0682","article-title":"Novel prostate-specific promoter derived from PSA and PSMA enhancers","volume":"6","author":"Lee","year":"2002","journal-title":"Mol Ther"},{"key":"10.1002\/jps.20289_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pros.10117","article-title":"Anti-tumor effects of toxins targeted to the prostate specific membrane antigen","volume":"53","author":"Fracasso","year":"2002","journal-title":"Prostate"},{"key":"10.1002\/jps.20289_bb0020","first-page":"6783","article-title":"In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two gamma-linked glutamate residues at the COOH terminus","volume":"61","author":"Warren","year":"2001","journal-title":"Cancer Res"},{"issue":"2 Suppl 1","key":"10.1002\/jps.20289_bb0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0090-4295(01)01256-0","article-title":"In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter\/enhancer: A potential alternative approach to androgen deprivation therapy","volume":"58","author":"Uchida","year":"2001","journal-title":"Urology"},{"key":"10.1002\/jps.20289_bb0030","first-page":"198","article-title":"Technology evaluation: C242-DM1, ImmunoGen Inc.","volume":"3","author":"Smith","year":"2001","journal-title":"Curr Opin Mol Ther"},{"key":"10.1002\/jps.20289_bb0035","first-page":"2008","article-title":"Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (huJ591)","volume":"61","author":"Ballangrud","year":"2001","journal-title":"Cancer Res"},{"key":"10.1002\/jps.20289_bb0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/13543784.10.3.511","article-title":"PSMA specific antibodies and their diagnostic and therapeutic use","volume":"10","author":"Holmes","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1002\/jps.20289_bb0045","first-page":"6095","article-title":"An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer","volume":"60","author":"McDevitt","year":"2000","journal-title":"Cancer Res"},{"key":"10.1002\/jps.20289_bb0050","first-page":"217","article-title":"Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy","volume":"4","author":"Gong","year":"2000","journal-title":"Mol Urol"},{"key":"10.1002\/jps.20289_bb0055","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1006308826967","article-title":"Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers","volume":"18","author":"Gong","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"10.1002\/jps.20289_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6","article-title":"Evaluation of phase I\/II clinical trials in prostate cancer with dendritic cells and PSMA peptides","volume":"36","author":"Tjoa","year":"1998","journal-title":"Prostate"},{"key":"10.1002\/jps.20289_bb0065","first-page":"5237","article-title":"In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen","volume":"60","author":"Smith-Jones","year":"2000","journal-title":"Cancer Res"},{"key":"10.1002\/jps.20289_bb0070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1309\/Y6LPC0LR726L9DX9","article-title":"Anticancer antibodies","volume":"119","author":"Ross","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1002\/jps.20289_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1586\/14737140.3.1.107","article-title":"Antibody-based therapeutics in oncology","volume":"3","author":"Ross","year":"2003","journal-title":"Exp Rev Anticancer Ther"},{"key":"10.1002\/jps.20289_bb0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2003.05.137","article-title":"Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the canag antigen: A phase I pharmacokinetic, and biologic correlative study","volume":"21","author":"Tolcher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1002\/jps.20289_bb0085","first-page":"198","article-title":"Technology evaluation: C242-DM1","volume":"3","author":"Smith","year":"2001","journal-title":"Curr Opin Mol Ther"},{"key":"10.1002\/jps.20289_bb0090","doi-asserted-by":"crossref","first-page":"8618","DOI":"10.1073\/pnas.93.16.8618","article-title":"Eradication of large colon tumor xenografts by targeted delivery of maytansinoids","volume":"93","author":"Liu","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"10.1002\/jps.20289_bb0095","series-title":"US Patent 6,441,163","author":"Chari","year":"2002"},{"key":"10.1002\/jps.20289_bb0100","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","article-title":"Phase I trial of yttrium-90\u2014labeled anti\u2014prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer","volume":"22","author":"Milowsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1002\/jps.20289_bb0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0093-7754(03)00358-0","article-title":"Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen","volume":"30","author":"Bander","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1002\/jps.20289_bb0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1021\/bc000070v","article-title":"Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals","volume":"12","author":"Liu","year":"2001","journal-title":"Bioconjugate Chem"},{"key":"10.1002\/jps.20289_bb0115","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/ac970035q","article-title":"Calicheamicin derivatives conjugated to monoclonal antibodies: Determination of loading values and distributions by infrared and UV matrix-assisted laser desorption\/ionization mass spectrometry and electrospray ionization mass spectrometry","volume":"69","author":"Siegel","year":"1997","journal-title":"Anal Chem"},{"key":"10.1002\/jps.20289_bb0120","unstructured":"Guidance for Industry.Bioanalytical Method Validation by FDA.http:\/\/www.fda.gov\/cder\/guidance\/index.htm."},{"key":"10.1002\/jps.20289_bb0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/rcm.565","article-title":"Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry","volume":"16","author":"Marshall","year":"2002","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1002\/jps.20289_bb0130","first-page":"2105","article-title":"Optimized conditions for chelation of yttrium-90 DOTA immunoconjugates","volume":"39","author":"Kukis","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1002\/jps.20289_bb0135","first-page":"131","article-title":"A review of the capabilities of ICP\/MS for trace element analysis in body fluids and tissues","volume":"7","author":"Vanhoe","year":"1993","journal-title":"Trace Elem Electrolytes Health Dis"},{"key":"10.1002\/jps.20289_bb0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/clinchem\/36.2.247","article-title":"Screening trace elements and electrolytes in serum by inductively-coupled plasma emission spectrometry","volume":"36","author":"Melton","year":"1990","journal-title":"Clin Chem"},{"key":"10.1002\/jps.20289_bb0145","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/clinchem\/43.12.2303","article-title":"Minimizing interferences in the quantitative multielement analysis of trace elements in bioloical fluids by inductively coupled plasma mass spectrometry","volume":"43","author":"Hsuing","year":"1997","journal-title":"Clin Chem"},{"key":"10.1002\/jps.20289_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1385\/BTER:80:1:77","article-title":"Simultaneous measurement of the trace elements Al, As, B, Be, Cd, Co, Cu, Fe, Li, Mn, Mo, Ni, Rb, Se, Sr, and Zn in human serum and their references ranges by ICP\/MS in biological trace element research","volume":"80","author":"Forrer","year":"2001","journal-title":"Biol Trace Elem Res"},{"key":"10.1002\/jps.20289_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF02917413","article-title":"Multielement analysis of biological samples by inductively coupled plasma-mass spectrometry in biological trace element research","volume":"22","author":"Templeton","year":"1989","journal-title":"Biol Trace Elem Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916317403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916317403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T22:08:03Z","timestamp":1586124483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916317403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0022354916317403"],"URL":"https:\/\/doi.org\/10.1002\/jps.20289","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}